Terms: = Germ cell tumor AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
3100 results:
1. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract] [Full Text] [Related]
2. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
Du Y; Li R; Fu D; Zhang B; Cui A; Shao Y; Lai Z; Chen R; Chen B; Wang Z; Zhang W; Chu L
CNS Neurosci Ther; 2024 Apr; 30(4):e14717. PubMed ID: 38641945
[TBL] [Abstract] [Full Text] [Related]
3. Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced braf-mutant melanoma.
Li W; Zheng C; Xu X; Xia Y; Zhang K; Huang A; Zhang X; Zheng Y; Chen G; Zhang S
Cell Mol Biol Lett; 2024 Apr; 29(1):50. PubMed ID: 38594618
[TBL] [Abstract] [Full Text] [Related]
4. Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
Whitman ED; Totev TI; Jiang S; da Costa WL; Grebennik D; Wang H; Boca AE; Ayyagari R
BMC Cancer; 2024 Mar; 24(1):389. PubMed ID: 38539148
[TBL] [Abstract] [Full Text] [Related]
5. Investigational Approaches for treatment of Melanoma Patients Progressing After Standard of Care.
Fletcher KA; Johnson DB
Cancer J; 2024 Mar-Apr 01; 30(2):126-131. PubMed ID: 38527267
[TBL] [Abstract] [Full Text] [Related]
6. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?
Hadfield MJ; Sullivan RJ
Cancer J; 2024 Mar-Apr 01; 30(2):84-91. PubMed ID: 38527261
[TBL] [Abstract] [Full Text] [Related]
7. Metastatic Melanoma treatment in Special Populations.
Miceli M; Boatwright C; Mehnert JM
Cancer J; 2024 Mar-Apr 01; 30(2):71-78. PubMed ID: 38527259
[TBL] [Abstract] [Full Text] [Related]
8. treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.
Tarhini AA; Castellano E; Eljilany I
Cancer J; 2024 Mar-Apr 01; 30(2):54-70. PubMed ID: 38527258
[TBL] [Abstract] [Full Text] [Related]
9. The outcome in patients with braf-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
Kopecký J; Pásek M; Lakomý R; Melichar B; Mrazová I; Kubeček O; Arenbergerová M; Lemstrová R; Švancarová A; Tretera V; Hlodáková A; Žváčková K
Cancer Med; 2024 Mar; 13(5):e6982. PubMed ID: 38491825
[TBL] [Abstract] [Full Text] [Related]
10. Anti-PD-(L)1 plus braf/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ; Dimitriou F; Grover P; Hassel JC; Erdmann M; Forschner A; Johnson DB; Váraljai R; Lodde G; Placke JM; Krefting F; Zaremba A; Ugurel S; Roesch A; Schulz C; Berking C; Pöttgen C; Menzies AM; Long GV; Dummer R; Livingstone E; Schadendorf D; Zimmer L
Eur J Cancer; 2024 May; 202():113976. PubMed ID: 38484692
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.
Kim HJ; Kim YH
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474231
[TBL] [Abstract] [Full Text] [Related]
12. Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of
Ramakrishnan D; Brüningk SC; von Reppert M; Memon F; Maleki N; Aneja S; Kazerooni AF; Nabavizadeh A; Lin M; Bousabarah K; Molinaro A; Nicolaides T; Prados M; Mueller S; Aboian MS
AJNR Am J Neuroradiol; 2024 Apr; 45(4):475-482. PubMed ID: 38453411
[TBL] [Abstract] [Full Text] [Related]
13. Primary endobronchial melanoma: a case report and clinical management indications.
Barisione E; Boutros A; Mora M; Spagnolo F; Tanda ET; Genova C; Tagliabue E
BMC Pulm Med; 2024 Feb; 24(1):97. PubMed ID: 38402179
[TBL] [Abstract] [Full Text] [Related]
14. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Hieken TJ; Nelson GD; Flotte TJ; Grewal EP; Chen J; McWilliams RR; Kottschade LA; Yang L; Domingo-Musibay E; Dronca RS; Yan Y; Markovic SN; Dimou A; Montane HN; Erskine CL; Piltin MA; Price DL; Khariwala SS; Hui J; Strand CA; Harrington SM; Suman VJ; Dong H; Block MS
Nat Commun; 2024 Feb; 15(1):1430. PubMed ID: 38365756
[TBL] [Abstract] [Full Text] [Related]
15. Long-term survival with systemic therapy in the last decade: Can melanoma be cured?
Namikawa K; Nakano E; Ogata D; Yamazaki N
J Dermatol; 2024 Mar; 51(3):343-352. PubMed ID: 38358050
[TBL] [Abstract] [Full Text] [Related]
16. Promising response to vemurafenib and cobimetinib treatment for braf V600E mutated craniopharyngioma: a case report and literature review.
Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O
CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829
[TBL] [Abstract] [Full Text] [Related]
17. The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.
Habibi MA; Mirjani MS; Ahmadvand MH; Delbari P; Alasti O
Eur J Clin Pharmacol; 2024 May; 80(5):639-656. PubMed ID: 38345637
[TBL] [Abstract] [Full Text] [Related]
18. Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma.
Farah C; Mignion L; Jordan BF
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38339003
[TBL] [Abstract] [Full Text] [Related]
19. Lamivudine, Doravirine, and Cabotegravir Downregulate the Expression of Human Endogenous Retroviruses (HERVs), Inhibit cell Growth, and Reduce Invasive Capability in Melanoma cell Lines.
Zanrè V; Bellinato F; Cardile A; Passarini C; Monticelli J; Di Bella S; Menegazzi M
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338893
[TBL] [Abstract] [Full Text] [Related]
20. Alterations in Plasma Lipid Profiles Associated with Melanoma and Therapy Resistance.
Dei Cas M; Ciniselli CM; Vergani E; Ciusani E; Aloisi M; Duroni V; Verderio P; Ghidoni R; Paroni R; Perego P; Beretta GL; Gatti L; Rodolfo M
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338838
[TBL] [Abstract] [Full Text] [Related]
[Next]